Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Upgraded by Zacks Research

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued on Wednesday, Zacks reports.

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $67.67.

Prestige Consumer Healthcare Stock Down 2.6%

Shares of Prestige Consumer Healthcare stock opened at $44.68 on Wednesday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. Prestige Consumer Healthcare has a 1 year low of $42.62 and a 1 year high of $71.07. The business has a 50-day moving average of $50.06 and a two-hundred day moving average of $51.33. The company has a market capitalization of $2.12 billion, a P/E ratio of 12.51, a price-to-earnings-growth ratio of 1.44 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The firm had revenue of $265.71 million for the quarter, compared to analysts’ expectations of $253.02 million. During the same quarter in the previous year, the business posted $0.90 EPS. The business’s quarterly revenue was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, equities analysts predict that Prestige Consumer Healthcare will post 4.56 EPS for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several large investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Prestige Consumer Healthcare during the second quarter valued at about $370,187,000. Rice Hall James & Associates LLC purchased a new stake in Prestige Consumer Healthcare in the second quarter worth $32,602,000. The Manufacturers Life Insurance Company bought a new position in Prestige Consumer Healthcare in the second quarter worth about $31,135,000. Norges Bank bought a new position in shares of Prestige Consumer Healthcare in the 4th quarter worth approximately $36,954,000. Finally, Bank of America Corp DE purchased a new position in Prestige Consumer Healthcare during the second quarter valued at $26,277,000. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, markets and distributes over-the-counter (OTC) products and household health-care brands. Its portfolio includes products for eye care, oral care, gastrointestinal health, pain relief, respiratory health, women’s health, and other everyday health needs.

The company’s brands include Dramamine, Bonine, BC, Goody’s, Clear Eyes, TheraTears, Monistat, Summer’s Eve, Vagisil, Luden’s, Chloraseptic, Compound W, Fleet and Debrox.